A Promising Future for the Global Vasomotor Symptoms Market driven by Increasing Menopausal Women Population
The global vasomotor symptoms market is witnessing steady growth due to its growing applications in improving symptoms like hot flashes and night sweats among menopausal women. Vasomotor symptoms treatment aims to provide relief from temperature dysregulation and related physiological changes during menopause transition by regulating hormones. Some of the commonly prescribed drugs for vasomotor symptoms include estrogen treatments, SNRIs (Serotonin–norepinephrine reuptake inhibitors), and SSRIs (Selective serotonin reuptake inhibitors).
The Vasomotor Symptoms Market is estimated to be valued at USD 3.71 billion in 2024 and is expected to reach USD 6.40 billion by 2031, growing at a compound annual growth rate (CAGR) of 6.8% from 2024 to 2031.
Key Takeaways
operating in the vasomotor symptoms market are Pfizer Inc., Novartis AG, Novo Nordisk A/S, Allergan plc, and Teva Pharmaceutical Industries Ltd.
Growing geriatric population globally has increased the number of women experiencing Vasomotor Symptoms Market due to menopause, fueling demand for effective treatment options. According to the National Institutes of Health, around 60% of women aged 50–59 years and around 25% of women aged 60–69 years experience hot flashes.
Get more insights on - Vasomotor Symptoms Market
Get this Report in Japanese Language: 血管運動症状市場
Get this Report in Korean Language: 혈관 운동 증상 시장
English
Arabic
Français
Español
Português
Deutsch
Dutch
Italiano
Russian
Romaian